GHK: COPD and emphysema use claims — US9585930B2
Avrum Spira, Marc Lenburg, Joshua Campbell, Dimitri Petchkovski, Darryl Andrew Knight, James Cameron Hogg, Julie Erin Zeskind Gil · 2017 · US9585930B2 · patent family 45922835
Published 2017-03-07.
Reported patent results
Reported findings
GHK reversed aspects of emphysema-associated expression patterns in laboratory analyses and increased selected repair-associated signals.
Human lung-tissue gene-expression discovery followed by GHK experiments in lung fibroblasts; tissue donors were not treated with GHK.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Expression signature | GHK-induced changes were anti-correlated with regional emphysema severity | Computational signature matching · p=0.006 |
| Lung-fibroblast confirmation | GHK-responsive gene sets were reproduced in fibroblast cultures | A cell experiment, not an improvement in patient lung function |
| β1-integrin combination assay | GHK plus TGF-β1 produced more β1-integrin than TGF-β1 alone | Cellular endpoint; no clinical COPD treatment was tested · p<0.01 |
Gene-expression reversal and cell responses do not demonstrate treatment of COPD, improved spirometry or human benefit from GHK-Cu. Related journal and patent descriptions are not independent trials.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Use. The claims concern GHK-related treatment of obstructive pulmonary disease; a dependent claim explicitly specifies GHK without copper.
The free peptide and its copper complex are not automatically interchangeable, and a grant does not establish clinical pulmonary benefit.
- Publication
- US9585930B2 ↗ · 2017-03-07
- Earliest priority / filing
- 2011-03-20 / 2012-03-20
- Original applicant / assignee
- University of British Columbia; Boston University
- Indexed status
- Active · checked 2026-11-06
- Patent family
- 45922835 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Therapeutic agent for emphysema and COPD
Inventors: Avrum Spira; Marc Lenburg; Joshua Campbell; Dimitri Petchkovski; Darryl Andrew Knight; James Cameron Hogg; Julie Erin Zeskind Gil.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- The free peptide and its copper complex are not automatically interchangeable, and a grant does not establish clinical pulmonary benefit.
- Gene-expression reversal and cell responses do not demonstrate treatment of COPD, improved spirometry or human benefit from GHK-Cu. Related journal and patent descriptions are not independent trials.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-45922835. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Avrum Spira, Marc Lenburg, Joshua Campbell, Dimitri Petchkovski, Darryl Andrew Knight, James Cameron Hogg, Julie Erin Zeskind Gil. GHK: COPD and emphysema use claims — US9585930B2 US9585930B2 · patent family 45922835 2017.
Molekul research summary: https://molekul.io/research/patent-us9585930b2. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry